J Clin Oncol. Oncol Rep. Int J Mol Sci. Prevention of cancer by inhibiting aging. Cancer Biol Ther. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.
Am J Pathol. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation TM. Cell Rep. Immunosuppressants in cancer prevention and therapy. Rapamycin extends maximal lifespan in cancer-prone mice.
Cancer Prev Res Phila. Longevity, aging and rapamycin. Cell Mol Life Sci. Fasting and rapamycin: diabetes versus benevolent glucose intolerance. Cell Death Dis. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1.
Cell Metab. TOR signaling in growth and metabolism. J Clin Invest. Nat Rev Mol Cell Biol. Curr Opin Genet Dev. The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability.
Zhou W, Ye S. Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy. Cell Biol Int. Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes. Mol Immunol. Rapamycin reverses insulin resistance IR in high-glucose medium without causing IR in normoglycemic medium. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice.
PLoS One. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med Berl. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.
Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol. Lundbaek K. Metabolic abnormalities in starvation diabetes. Yale J Biol Med. Peters JP. Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production.
Age Dordr. Population response to information on reversibility of Type 2 diabetes. Diabet Med. Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Koffler M, Kisch ES. Starvation diet and very-low-calorie diets may induce insulin resistance and overt diabetes mellitus.
J Diabetes Complications. The mystery of the ketogenic diet: benevolent pseudo-diabetes. Nutr Diabetes. What are we to think when results from mouse research contradict those from human experiments and clinical practice?
Low carbohydrate high fat diets: when models do not match reality. Arch Endocrinol Metab. In silico clinical trials for anti-aging therapies. Longo VD, Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. Manipulation of health span and function by dietary caloric restriction mimetics. Ann N Y Acad Sci. Rapamycin-induced glucose intolerance: hunger or starvation diabetes.
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. Kidney Int. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential.
The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci. Nephrol Dial Transplant. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. Acta Oncol. Clin Genitourin Cancer. The clinical course and potential underlying mechanisms of everolimus-induced hyperglycemia.
Endocr J. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Sirolimus-based immunosuppression in kidney transplantation for type 2 diabetic nephropathy. Urol Int. Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.
New-onset diabetes after transplantation: a threat to graft and patient survival. Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation. Clin Dev Immunol. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
Transplant-associated hyperglycemia: a new look at an old problem. Clin J Am Soc Nephrol. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. Thorat MA, Cuzick J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol.
Acute sirolimus overdose: a multicenter case series. Pharmacokinetics and safety of single oral doses of sirolimus rapamycin in healthy male volunteers. Ther Drug Monit. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature. Mammalian target of rapamycin regulates a hyperresponsive state in pulmonary neutrophils late after burn injury.
J Leukoc Biol. Single rapamycin administration induces prolonged downward shift in defended body weight in rats. Sci Signal. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. Johnson SC, Kaeberlein M. Rapamycin in aging and disease: maximizing efficacy while minimizing side effects.
Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet. Comparison of rapamycin schedules in mice on high-fat diet. Kaeberlein M. Rapamycin and ageing: when, for how long, and how much? J Genet Genomics. Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells. Rejuvenation Res. Harman D, Harman H. Interview by K. Kitani and G.
Lapointe J, Hekimi S. When a theory of aging ages badly. Ristow M, Schmeisser K. Dose Response. Gems D, Partridge L. Genetics of longevity in model organisms: debates and paradigm shifts. Annu Rev Physiol. Gems D, de la Guardia Y. Antioxid Redox Signal. Howes RM. The free radical fantasy: a panoply of paradoxes. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?
Antioxidant supplements and mortality. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. Antioxidants prevent health-promoting effects of physical exercise in humans.
Ristow M, Schmeisser S. Extending life span by increasing oxidative stress. Free Radic Biol Med. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.
J Natl Cancer Inst. Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial. Oxidative stress inhibits distant metastasis by human melanoma cells. Antioxidants accelerate lung cancer progression in mice. Antioxidants can increase melanoma metastasis in mice. Growth hormone deficiency: health and longevity. Endocr Rev.
Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice. Bartke A, Quainoo N. Effects of human growth hormone in men over 60 years old.
Vance ML. Can growth hormone prevent aging? Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Genetics: influence of TOR kinase on lifespan in C. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway.
Curr Biol. The TOR pathway comes of age. Biochim Biophys Acta. Cell senescence and hypermitogenic arrest. EMBO Rep. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Validation of anti-aging drugs by treating age-related diseases. Disease or not, aging is easily treatable. Aging is not programmed: genetic pseudo-program is a shadow of developmental growth. Monsters in the uterus: teratoma-like tumors in senescent C.
Rapamycin and quasi-programmed aging: four years later. From rapalogs to anti-aging formula. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.
Adaptations to chronic rapamycin in mice. Pathobiol Aging Age Relat Dis. Swindell WR. Rapamycin in mice. Prospective treatment of age-related diseases by slowing down aging. Koschei the immortal and anti-aging drugs. Functional status will be measured using the functional assessment scale FAS.
Gait speed will be evaluated with an electronic gait mat. Grip strength will be evaluated with a hand dynamometer. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials. Layout table for location contacts Contact: Mitzi Gonzales, Phd gonzalesm20 uthscsa. More Information. Cognition Alzheimer's disease biomarkers Neuroimaging. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Mild Cognitive Impairment Alzheimer Disease. Drug: Rapamycin Other: Placebo. Phase 2.
Study Type :. Interventional Clinical Trial. Estimated Enrollment :. Actual Study Start Date :. Estimated Primary Completion Date :. Estimated Study Completion Date :. Inclusion Criteria: Age Any sex Any ethnicity Interest in taking Rapamycin off-label Willing to undergo tests Relatively good health with only well-managed chronic diseases hypertension, coronary artery disease, type II diabetes, etc. Enbrel, Humira, methotrexate. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials. More Information. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Drug: Rapamycin Drug: Placebo. Phase 2. Study Type :. Interventional Clinical Trial.
Estimated Enrollment :. Actual Study Start Date :. Estimated Primary Completion Date :. Estimated Study Completion Date :.
0コメント